Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Worcester, MA
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Worcester, MA
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Springfield, MO
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Springfield, MO
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Billings, MT
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Asheville, NC
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Columbus, OH
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Charleston, SC
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Corpus Christi, TX
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Houston, TX
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Killeen, TX
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Killeen, TX
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Round Rock, TX
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Temple, TX
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Ogden, UT
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated:  8/13/2014
Clinical Research Facility
mi
from
Seattle, WA
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status: Enrolling
Updated: 8/13/2014
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
Status: Enrolling
Updated:  8/15/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
Status: Enrolling
Updated: 8/15/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer
Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer
Status: Enrolling
Updated:  8/19/2014
University of Alabama at Birmingham
mi
from
Birmingham, AL
Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer
Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer
Status: Enrolling
Updated: 8/19/2014
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated:  8/26/2014
Rhode Island Comprehensive Cancer Center at East Greenwich
mi
from
East Greenwich, RI
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated: 8/26/2014
Rhode Island Comprehensive Cancer Center at East Greenwich
mi
from
East Greenwich, RI
Click here to add this to my saved trials
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated:  8/26/2014
Rhode Island Hospital
mi
from
Providence, RI
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated: 8/26/2014
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated:  8/26/2014
Miriam Hospital
mi
from
Providence, RI
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated: 8/26/2014
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Investigating the Impact of Tamoxifen Therapy on Ovarian Aging
Investigating the Impact of Tamoxifen Therapy on Ovarian Aging
Status: Enrolling
Updated:  8/27/2014
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Investigating the Impact of Tamoxifen Therapy on Ovarian Aging
Investigating the Impact of Tamoxifen Therapy on Ovarian Aging
Status: Enrolling
Updated: 8/27/2014
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated:  9/3/2014
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated: 9/3/2014
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated:  9/3/2014
Aurora St.Luke's Medical Center
mi
from
Milwaukee, WI
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated: 9/3/2014
Aurora St.Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Phase IB With Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/17/2014
Swedish Medical Center Cancer Institute
mi
from
Seattle, WA
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Phase IB With Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/17/2014
Swedish Medical Center Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Improved Breast MRI With SWIFT
Improved Breast Dynamic Contrast Enhanced-magnetic Resonance Imaging (DCE-MRI) With Sweep Imaging With Fourier Transform (SWIFT)
Status: Enrolling
Updated:  9/18/2014
Center for Magnetic Resonance Research
mi
from
Minneapolis, MN
Improved Breast MRI With SWIFT
Improved Breast Dynamic Contrast Enhanced-magnetic Resonance Imaging (DCE-MRI) With Sweep Imaging With Fourier Transform (SWIFT)
Status: Enrolling
Updated: 9/18/2014
Center for Magnetic Resonance Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Cardiopulmonary Research Science & Technology Institute
mi
from
Dallas, TX
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Cardiopulmonary Research Science & Technology Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Geisinger Medical Center
mi
from
Danville, PA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Group Health Research Institute
mi
from
Seattle, WA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Group Health Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Henry Ford Hospital
mi
from
Detroit, MI
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Intermountain Healthcare
mi
from
Murray, UT
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Intermountain Healthcare
mi
from
Murray, UT
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Kaiser Permanente Northern California
mi
from
San Francisco, CA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Kaiser Permanente Northern California
mi
from
San Francisco, CA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
North East Alabama Regional Medical Center
mi
from
Anniston, GA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
North East Alabama Regional Medical Center
mi
from
Anniston, GA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
University of Cincinnati
mi
from
Cincinnati, OH
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
LEVEL UP: Video Games for Activity in Breast Cancer Survivors
LEVEL UP: Leveraging Electronic Videogames for Exercise and Leisure: Understanding Preferences of Breast Cancer Survivors
Status: Enrolling
Updated:  9/29/2014
University of Texas Medical Branch
mi
from
Galveston, TX
LEVEL UP: Video Games for Activity in Breast Cancer Survivors
LEVEL UP: Leveraging Electronic Videogames for Exercise and Leisure: Understanding Preferences of Breast Cancer Survivors
Status: Enrolling
Updated: 9/29/2014
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
Status: Enrolling
Updated:  10/14/2014
The Center for Cancer Prevention & Treatment at St. Joseph Hospital of Orange
mi
from
Orange, CA
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
Status: Enrolling
Updated: 10/14/2014
The Center for Cancer Prevention & Treatment at St. Joseph Hospital of Orange
mi
from
Orange, CA
Click here to add this to my saved trials
SmartScope vs Standard Colposcope for the Evaluation of Cervical Dysplasia
Image Comparison of a Mobile Colposcope (SmartScope) vs. a Standard Colposcope for Directing Cervical Biopsies in Women With Abnormal Pap Smears: A Non-inferiority Trial.
Status: Enrolling
Updated:  10/21/2014
Scripps Clinic
mi
from
San Diego, CA
SmartScope vs Standard Colposcope for the Evaluation of Cervical Dysplasia
Image Comparison of a Mobile Colposcope (SmartScope) vs. a Standard Colposcope for Directing Cervical Biopsies in Women With Abnormal Pap Smears: A Non-inferiority Trial.
Status: Enrolling
Updated: 10/21/2014
Scripps Clinic
mi
from
San Diego, CA
Click here to add this to my saved trials
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Status: Enrolling
Updated:  10/27/2014
Rieman Cancer Center
mi
from
Milwaukee, WI
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Status: Enrolling
Updated: 10/27/2014
Rieman Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Status: Enrolling
Updated:  10/27/2014
WFH-St. Francis
mi
from
Milwaukee, WI
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Status: Enrolling
Updated: 10/27/2014
WFH-St. Francis
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Status: Enrolling
Updated:  10/27/2014
Wheaton Franciscan Healthcare - St. Joseph Campus
mi
from
Milwaukee, WI
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Status: Enrolling
Updated: 10/27/2014
Wheaton Franciscan Healthcare - St. Joseph Campus
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Status: Enrolling
Updated:  10/27/2014
Wheaton Franciscan - Wauwatosa Campus
mi
from
Wauwatosa, WI
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Status: Enrolling
Updated: 10/27/2014
Wheaton Franciscan - Wauwatosa Campus
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer
A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/3/2014
Roger Williams Medical Center
mi
from
Providence, RI
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer
A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/3/2014
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors
Status: Enrolling
Updated:  11/3/2014
Roger Willaims Medical Center
mi
from
Providence, RI
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors
Status: Enrolling
Updated: 11/3/2014
Roger Willaims Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Southern Cancer Center PC SC
mi
from
Mobile, AL
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Southern Cancer Center PC SC
mi
from
Mobile, AL
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Ironwood Cancer and Research Centers SC
mi
from
Chandler, AZ
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Ironwood Cancer and Research Centers SC
mi
from
Chandler, AZ
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
City of Hope National Medical Center COH 3
mi
from
Duarte, CA
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
City of Hope National Medical Center COH 3
mi
from
Duarte, CA
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
University of California San Diego Moores UCSD Cancer Ctr. SC-1
mi
from
La Jolla, CA
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
University of California San Diego Moores UCSD Cancer Ctr. SC-1
mi
from
La Jolla, CA
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Cedars Sinai Medical Center Samuel Oschin Cancer Center
mi
from
Los Angeles, CA
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Cedars Sinai Medical Center Samuel Oschin Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials